Sleep device manufacturer ResMed has confirmed an exemption to US tariffs, surging quarterly earnings and an enviable balance sheet, but the company's boss is not napping on the result.
The ASX-listed company lifted its third-quarter revenue eight per cent to $1.3 billion, boosted its earnings per share by more than a fifth and reported operating cash flow of $579 million.
